17 янв. 2023 г. · Sunlenca FDA Approval History. Last updated by Judith Stewart, BPharm on Jan 17, 2023. FDA Approved: Yes (First approved December 22, 2022)

24 мар. 2023 г. · The FDA recently granted approval to lenacapavir (LEN), a novel long-acting HIV antiretroviral (ARV) that is classified as a capsid inhibitor. ...

Lenacapavir (brand name: Sunlenca) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in ...

30 авг. 2023 г. · Lenacapavir is a new FDA-approved HIV injection that is safe, highly effective, and taken only twice per year. Its approval was based on ...

Lenacapavir is an investigational compound and is not approved by any regulatory authority for any use and its safety and efficacy are not established.

In May 2019, the FDA granted Breakthrough Therapy Designation for the development of lenacapavir for the treatment of HIV-1 infection in heavily treatment- ...

10 янв. 2023 г. · The FDA has approved Gilead Science's first-in-class capsid inhibitor lenacapavir, providing a new treatment option for people with multidrug-resistant HIV.

Lenacapavir is a drug that has been approved by the U.S. Food and Drug Administration (FDA) under the brand name Sunlenca for the treatment of HIV.

Lenacapavir was detected at low levels in the plasma of nursing rat pups in the pre/postnatal development study (post-natal day 10). The safety and ...